Checkmate Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Checkmate Pharmaceuticals's estimated annual revenue is currently $2.6M per year.
- Checkmate Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- Checkmate Pharmaceuticals has 17 Employees.
- Checkmate Pharmaceuticals grew their employee count by 0% last year.
Checkmate Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder, CSO | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | VP, Development Operations | Reveal Email/Phone |
4 | Chief Business Officer | Reveal Email/Phone |
5 | Manager, CMC Project Management | Reveal Email/Phone |
6 | President and CEO | Reveal Email/Phone |
Checkmate Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Checkmate Pharmaceuticals?
Checkmate Pharmaceuticals is a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat cancer.
keywords:N/A
N/A
Total Funding
17
Number of Employees
$2.6M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Checkmate Pharmaceuticals News
2022-04-20 - Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major ...
Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Global Strategic Fund I. Venbio Sells 27,668 Shares. Posted by admin on Apr 26th...
2022-04-19 - Regeneron forks out $250m to buy Checkmate - BioProcess ...
Regeneron will increase its research efforts in immuno-oncology through the all-cash acquisition of Checkmate Pharmaceuticals.
2022-04-13 - Regeneron buys Checkmate Pharmaceuticals for $250M cash
Regeneron plans to show there is more to skin cancer than PD-1 inhibitors through the $250 million acquisition of Checkmate Pharmaceuticals...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.5M | 17 | -78% | $305.9M |
#2 | $3.5M | 17 | -6% | N/A |
#3 | $1.5M | 17 | N/A | N/A |
#4 | $1.5M | 17 | 6% | N/A |
#5 | $1.8M | 17 | 31% | N/A |